Literature DB >> 16583266

Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence.

Hulin Wu1, Yangxin Huang, Edward P Acosta, Jeong-Gun Park, Song Yu, Susan L Rosenkranz, Daniel R Kuritzkes, Joseph J Eron, Alan S Perelson, John G Gerber.   

Abstract

We developed a novel HIV-1 dynamic model with consideration of pharmacokinetics, drug adherence and drug susceptibility to link plasma drug concentration to the long-term changes in HIV-1 RNA observation after initiation of therapy. A Bayesian approach is proposed to fit this model to clinical data from ACTG A5055, a study of two dosage regimens of indinavir (IDV) with ritonavir (RTV) in subjects failing their first protease inhibitor treatment. The HIV RNA testing was completed at days 0, 7, 14, 28, 56, 84, 112, 140, and 168. An intensive pharmacokinetic (PK) evaluation was performed on day 14 and multiple trough concentrations were subsequently collected. Pill counts were used to monitor adherence. IC(50) for IDV and RTV were determined at baseline and at virologic failure. Viral dynamic model fitting residuals were used to assess the significance of covariate effects on long-term virologic response. As univariate predictors, none of the four PK parameters C(trough), C(12 hour), C(max), and AUC was significantly related to virologic response (p > 0.05). By including drug susceptibility (IC(50)), or IC(50) and adherence measured by pill counts together, C(trough), C(12 hour), C(max) and AUC were each significantly correlated to long-term virologic response (p = 0.0055,0.0002,0.0136,0.0002 with IC(50) and adherence measured by pill counts considered). The IC(50) and adherence measured by pill counts alone were not related to the virologic response. In predicting virologic response adherence measured by pill counts did not provide any additional information to PK parameters (p = 0.064), to drug susceptibility IC(50) (p = 0.086), and to their combination (p = 0.22). Simple regression approaches did not detect any significant pharmacodynamic (PD) relationships. Any single factor of PK, adherence measured by pill counts and drug susceptibility did not contribute to long-term virologic response. But their combinations in viral dynamic modeling significantly predicted virologic response. The HIV dynamic modeling can appropriately capture complicated nonlinear relationships and interactions among multiple covariates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16583266     DOI: 10.1007/s10928-006-9006-4

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  21 in total

1.  Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials.

Authors:  H Wu; A A Ding
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

2.  Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity.

Authors:  Yangxin Huang; Susan L Rosenkranz; Hulin Wu
Journal:  Math Biosci       Date:  2003-08       Impact factor: 2.144

Review 3.  Measuring the effectiveness of antiretroviral agents.

Authors:  N Buss; N Cammack
Journal:  Antivir Ther       Date:  2001-03

4.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

5.  Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.

Authors:  Nancy Shulman; Andrew Zolopa; Diane Havlir; Ann Hsu; Cheryl Renz; Sheila Boller; Ping Jiang; Richard Rode; Joel Gallant; Elizabeth Race; Dale J Kempf; Eugene Sun
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.

Authors:  Richard H Haubrich; Carol A Kemper; Nicholas S Hellmann; Philip H Keiser; Mallory D Witt; Donald N Forthal; John Leedom; Matthew Leibowitz; Jeannette M Whitcomb; Douglas Richman; J Allen McCutchan
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

7.  A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.

Authors:  Martin Markowitz; Michael Louie; Arlene Hurley; Eugene Sun; Michele Di Mascio; Alan S Perelson; David D Ho
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.

Authors:  K C Zachary; G J Hanna; R T D'Aquila
Journal:  Clin Infect Dis       Date:  2001-11-07       Impact factor: 9.079

9.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

Review 10.  Protein binding in antiretroviral therapies.

Authors:  Marta Boffito; David J Back; Terrence F Blaschke; Malcolm Rowland; Richard J Bertz; John G Gerber; Veronica Miller
Journal:  AIDS Res Hum Retroviruses       Date:  2003-09       Impact factor: 2.205

View more
  12 in total

1.  Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility.

Authors:  Libin Rong; Michael A Gilchrist; Zhilan Feng; Alan S Perelson
Journal:  J Theor Biol       Date:  2007-04-19       Impact factor: 2.691

2.  Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling.

Authors:  Philippe Jacqmin; Lynn McFadyen; Janet R Wade
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-03-04       Impact factor: 2.745

3.  A Bayesian Approach in Differential Equation Dynamic Models Incorporating Clinical Factors and Covariates.

Authors:  Yangxin Huang
Journal:  J Appl Stat       Date:  2010-02-01       Impact factor: 1.404

Review 4.  Mathematical modeling of within-host Zika virus dynamics.

Authors:  Katharine Best; Alan S Perelson
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

5.  Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors.

Authors:  Yangxin Huang; Hulin Wu; Edward P Acosta
Journal:  Biom J       Date:  2010-08       Impact factor: 2.207

Review 6.  Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation models.

Authors:  Yanni Xiao; Hongyu Miao; Sanyi Tang; Hulin Wu
Journal:  Adv Drug Deliv Rev       Date:  2013-04-17       Impact factor: 15.470

7.  Identifying significant covariates for anti-HIV treatment response: mechanism-based differential equation models and empirical semiparametric regression models.

Authors:  Yangxin Huang; Hua Liang; Hulin Wu
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

8.  Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.

Authors:  Patrick F Smith; Abayomi Ogundele; Alan Forrest; John Wilton; Karl Salzwedel; Judy Doto; Graham P Allaway; David E Martin
Journal:  Antimicrob Agents Chemother       Date:  2007-07-16       Impact factor: 5.191

9.  Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.

Authors:  Gerben van 't Klooster; Eva Hoeben; Herman Borghys; Adriana Looszova; Marie-Paule Bouche; Frans van Velsen; Lieven Baert
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

Review 10.  Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics.

Authors:  Alan S Perelson; Ruian Ke
Journal:  Clin Pharmacol Ther       Date:  2021-03-08       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.